The Business Opportunity
Vasgen is developing a semi-virtual, low-burn, operating model with a small but dynamic team of innovators committed to delivering first-in-class, AbIMPTM based therapeutics to meet unmet clinical needs in the ophthalmology and cancer space.
Vasgen’s lead product is a pre-clinical stage AbIMP targeting ADAM15 as a first-in-class anti-angiogenic therapeutic monoclonal antibody to treat ocular neovascular diseases and the aggressive forms of prostate and breast cancers, thereby potentially competing in the multi-billion dollar global anti-angiogenic market. Vasgen is currently seeking finance to progress development of its ADAM15 AbIMP to proof of concept in humans, whereupon an exit via a merger or acquisition is anticipated
Vasgen is also seeking finance to support development of an R & D programme to validate ADAMs and additional metzincins of therapeutic interest using its AbIMPTM technology as a pharmacological approach to supplement genetic models. This will facilitate development of therapeutic strategies to drug validated targets using AbIMPTM technology leading to a high value pipeline. Vasgen is also open to both partnering and out-licencing of its IP in order to accelerate development of novel therapeutic technologies.